Cancer News and Research

Latest Cancer News and Research

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.

26 Mar 2010

Single-incision laparoscopy reduces postoperative complications

Surgeons at the University of California, San Diego School of Medicine report what is believed to be the nation's first single-incision laparoscopy to perform a combined colectomy and kidney-preserving therapy.

26 Mar 2010

New experiments may hold clues for controlling cancer

A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

26 Mar 2010

Insulin receptor vital for keeping neural stem cells alive

University of California, Berkeley, biologists have found a signal that keeps stem cells alive in the adult brain, providing a focus for scientists looking for ways to re-grow or re-seed stem cells in the brain to allow injured areas to repair themselves.

26 Mar 2010

Researcher extracts natural scaffold for tissue growth

It frequently happens in science that what you throw away turns out to be most valuable. It happened to Deepak Nagrath, but not for long.

26 Mar 2010

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

About 40 percent of children and up to 70 percent of adults in remission from acute myelogenous leukemia will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, endlessly replicating cancer cells that generate the immature blood cells characteristic of leukemia and are resistant to typical cancer treatments.

26 Mar 2010

New report urges government to ban smoking in cars to limit children's exposure to passive smoke

A new report released by the Tobacco Advisory Group of the Royal College of Physicians urges the government to ban smoking in cars and other public vehicles to limit children's exposure to passive smoke.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

New gateway may be lifesaver for patients with AML: Study

Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Fluidigm, SABiosciences partner to create pathway-focused gene expression panels for BioMark system

Fluidigm Corporation and SABiosciences (a QIAGEN Company) today announced that they have teamed up to create over 100 pathway-focused gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System for Genetic Analysis. These kits are named the RT² Profiler™ PCR Arrays for the Fluidigm BioMark system.

26 Mar 2010

Standard HCV therapy less effective in urban minority patients: Study

A recent study confirms that the standard hepatitis C therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

26 Mar 2010

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the Phase III ACCESS trial.

26 Mar 2010

Hana Biosciences reports net loss of $5M for fourth quarter 2009

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the fourth quarter and year ended December 31, 2009, and provided a corporate update.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

GPC5 gene associated with lung cancer in 'never-smokers'

US scientists have identified a gene that may be responsible for a proportion of lung cancer cases among people who have never smoked.

26 Mar 2010

DARA BioSciences announces the initiation of Phase I clinical study for DB959

DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.

26 Mar 2010

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

Genomic Health, Inc. today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe's leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX® breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th European Breast Cancer Conference (EBCC), further expands the global presence of Oncotype DX, providing for increased physician and patient access to this advanced diagnostic test in the European market.

26 Mar 2010

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels.

26 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Single-incision laparoscopy reduces postoperative complications

New experiments may hold clues for controlling cancer

Insulin receptor vital for keeping neural stem cells alive

Researcher extracts natural scaffold for tissue growth

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

New report urges government to ban smoking in cars to limit children's exposure to passive smoke

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

New gateway may be lifesaver for patients with AML: Study

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Fluidigm, SABiosciences partner to create pathway-focused gene expression panels for BioMark system

Standard HCV therapy less effective in urban minority patients: Study

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

Hana Biosciences reports net loss of $5M for fourth quarter 2009

AVASTIN receives Health Canada approval for patients with GBM

GPC5 gene associated with lung cancer in 'never-smokers'

DARA BioSciences announces the initiation of Phase I clinical study for DB959

Palex Medical to distribute Genomic Health's Oncotype DX breast cancer test in Spain and Portugal

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

JCOM receives approval from KFDA to commercialize MuGard in Korea

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in